Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.43 |
| ▸ | THRB known ✓ | P10828 | 3/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.40 |
| ▸ | APEX1 | P27695 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356610 | 1.00 | SLC7A11 (0.44) | SLC7A11CA2CA3USP2PTPN1 | |
| SCHEMBL840203 | 1.00 | SLC7A11 (0.44) | SLC7A11CA2CA3USP2PTPN1 | |
| SCHEMBL4801447 | 0.93 | CD40 (0.46) | SLC7A11CA2CA3THRBAMY1A | |
| SCHEMBL4801488 | 0.93 | CD40 (0.46) | SLC7A11CA2CA3THRBAMY1A | |
| SCHEMBL3756084 | 0.91 | THRB (0.42) | SLC7A11CA2CA3USP2PTPN1 | |
| SCHEMBL31279977 | 0.86 | PRMT1 (0.48) | CA2CA3THRBAMY1AF11 | |
| SCHEMBL184756 | 0.85 | CA2 (0.52) | CA2CA3THRBKMT2ATDP1 | |
| SCHEMBL18775362 | 0.85 | CA2 (0.52) | CA2CA3THRBKMT2ATDP1 | |
| SCHEMBL6120387 | 0.85 | CA2 (0.52) | CA2CA3THRBKMT2ATDP1 | |
| SCHEMBL8647387 | 0.85 | CA2 (0.52) | CA2CA3THRBKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019216829-A1 | APPLICATION OF A FOOD AZO DYE, BRILLIANT BLACK BN, ON INHIBITION OF INFECTIVITY OF HUMAN ENTEROVIRUSES CAUSING HAND FOOT AND MOUTH DISEASES | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2019-11-14 | — | — | WO | claimed |
| US-20050147673-A1 | Directly compressible sustained release formulation containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2005-07-07 | — | — | US | claimed |
| US-6395303-B1 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | EDWARD MENDELL CO., INC. | 2002-05-28 | — | — | US | claimed |
| US-6106865-A | MIXTURE OF MICROCRYSTALLINE CELLULOSE, COMPRESSIBILITY, SILICA AND SURFACTANTS | EDWARD MENDELL CO., INC. (US) | 2000-08-22 | — | — | US | claimed |
| US-20250381158-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | NEUROCENTRIA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | disclosed |
| US-20240207209-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230355556-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230116091-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220249412-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11298330-B2 | Magnesium compositions and methods of use | NEUROCENTRIA, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210393561-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20060008522-A1 | Agglomerate of microcrystalline cellulose and silica; controlling particle size | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2006-01-12 | — | — | US | disclosed |
| US-6936277-B2 | Pharmaceutical excipient having improved compressibility | J. RETTENMAIER & SOEHNE GMBH & CO. KG (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20050147673-A1 | Directly compressible sustained release formulation containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2005-07-07 | — | — | US | disclosed |
| US-6866867-B2 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20030099702-A1 | Pharmaceutical excipient having improved compressibility | PENWEST PHARMACEUTICALS CO. | 2003-05-29 | — | — | US | disclosed |
| US-20020182259-A1 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2002-12-05 | — | — | US | disclosed |
| US-6395303-B1 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | EDWARD MENDELL CO., INC. | 2002-05-28 | — | — | US | disclosed |
| US-6106865-A | MIXTURE OF MICROCRYSTALLINE CELLULOSE, COMPRESSIBILITY, SILICA AND SURFACTANTS | EDWARD MENDELL CO., INC. (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393561-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CA2 1967/4885THRB 722/4885SLC7A11 48/4885 |
| US-20240207209-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CA2 1967/4885THRB 722/4885SLC7A11 48/4885 |
| US-20230116091-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CA2 1967/4885THRB 722/4885SLC7A11 48/4885 |
| US-20250381158-A1 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS | MAPT, PYGB, ACHE | CA2 710/4885THRB 2393/4885SLC7A11 78/4885 |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | AHCY, MGMT, CBS | CA2 2537/4885THRB 3014/4885SLC7A11 21/4885 |
| US-20220249412-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CA2 1967/4885THRB 722/4885SLC7A11 48/4885 |
| US-11298330-B2 | Magnesium compositions and methods of use | SLC5A6, SLC6A6, SLC6A5 | CA2 166/4885THRB 1274/4885SLC7A11 48/4885 |
| US-20230355556-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CA2 1967/4885THRB 722/4885SLC7A11 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.